A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Fresno, California 93720, United States
Greater Sudbury, Ontario P3E 5J1, Canada
Ile-de-france, 93009, France
Lódz, 93-510, Poland